Results 31 to 40 of about 2,175,372 (155)
Integrin subunit beta 8 contributes to lenvatinib resistance in HCC
Hepatology Communications, 2022 Lenvatinib is a multikinase inhibitor approved as a first‐line therapy for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the underlying mechanisms governing this resistance are largely unknown.
Wei Hou +6 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Lenvatinib is the latest and promising agent that has demonstrated a significant improvement of progression-free survival in advanced hepatocellular carcinoma (HCC). However, resistance emerges soon after initial treatment, limiting the clinical benefits
Jun Guo +37 more
doaj +1 more source
Hepatology, EarlyView., 2022 Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou +13 more
wiley +1 more source
Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance
Cell Death Discovery, 2021 Lenvatinib is the first target drug approved for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the mechanisms of lenvatinib resistance and resistant targets in HCC are poorly understood.
Yonggang Lu +7 more
doaj +1 more source
Translational Oncology, 2021 Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Lenvatinib oral chemotherapy is approved as a first-line treatment of patients with unresectable HCC.
Yarong Guo +4 more
doaj +1 more source
c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis
Hepatology, EarlyView., 2022 In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie +17 more
wiley +1 more source
, 2021 症例は慢性C 型肝炎に罹患し飲酒習慣もある60 歳代男性で，原発性肝細胞癌の一部に破裂予防の肝動脈塞栓術施行後，lenvatinib 8 mg/日を開始した．約1 カ月で腫瘍に感染し，抗生剤治療不応かつ経皮的ドレナージ困難にて，lenvatinib を一週間休薬し，開腹下感染腫瘍切除術を施行した．術後創部治癒に問題なく，lenvatinib を4 mg/日で再開したが，肝障害，倦怠感，食思不振で35 日間休薬した．dexamethasone 併用して再開し，8 mg/日まで増量したが動脈血流減少せず ...
谷, 眞至 +33 more
core +1 more source
Evaluating the effect of lenvatinib on sorafenib-resistant hepatocellular carcinoma cells [PDF]
, 2022 香川大学Kagawa University博士（医学）Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related deaths worldwide. Sorafenib has been used as a first-line systemic treatment for over a decade.
石, 婷婷 +2 more
core +3 more sources
, 2022 Drug resistance has greatly limited the clinical efficacy of lenvatinib in hepatocellular carcinoma (HCC). However, the underlying molecular mechanisms of lenvatinib resistance remain largely undetermined.
Zhenbin Ding (8444055) +13 more
core +1 more source
, 2021 Lenvatinib is the latest and promising agent that has demonstrated a significant improvement of progression-free survival in advanced hepatocellular carcinoma (HCC). However, resistance emerges soon after initial treatment, limiting the clinical benefits
Yan Shu (441370) +9 more
core +1 more source